modelJ05AF07
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | TenofovirDisoproxil | |
| ATC code: | J05AF07 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 96.7 | L |
| clearance: | 12.6 | L/h |
| other parameters in model implementation | ||
Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NRTI) used as an antiretroviral medication for the treatment and prevention of HIV-1 infection and chronic hepatitis B. It is approved and widely used today as part of combination therapy regimens.
Pharmacokinetics
Pharmacokinetic parameters in healthy adults following single oral dose of tenofovir disoproxil 300 mg.
References
Eke, AC, et al., & Capparelli, EV (2021). Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02168-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318014
Burns, RN, et al., & Chaturvedula, A (2015). Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. Journal of clinical pharmacology 55(6) 629–638. DOI:10.1002/jcph.461 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25581815
Kearney, BP, et al., & Shah, J (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics 43(9) 595–612. DOI:10.2165/00003088-200443090-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15217303
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)